Current Report Filing (8-k)
June 21 2017 - 9:04AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 19, 2017
MYRIAD GENETICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
0-26642
|
|
87-0494517
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
320 Wakara Way
Salt Lake City, Utah 84108
(Address of principal executive offices) (Zip Code)
Registrants telephone number, including area code: (801) 584-3600
Not Applicable
(Former
name or former address, if changed since last report)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On June 19, 2017, Myriad Genetics, Inc. (Myriad or the
Company) agreed on a new long-term relationship with UnitedHealthcare that established pricing for its hereditary cancer tests, GeneSight
®
, Prolaris
®
, Vectra
®
DA and EndoPredict
®
. New product coverage will be determined based on a
members benefit plan. Additional terms of the deal are not disclosed.
Page 2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
MYRIAD GENETICS, INC.
|
|
|
|
|
Date: June 21, 2017
|
|
|
|
By:
|
|
/s/ R. Bryan Riggsbee
|
|
|
|
|
|
|
R. Bryan Riggsbee
|
|
|
|
|
|
|
Executive Vice President, Chief Financial Officer
|
Page 3
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2024 to May 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From May 2023 to May 2024